Brooklyn Immunotherapeutics   Report issue

For profit Phase 2
Founded: Brooklyn NY United States (2018)
Status: Acquired by IRX Therapeutics (2018)

Organization Overview

First Clinical Trial
2018
NCT03267680
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Brooklyn ImmunoTherapeutics, LLC

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Breast Neoplasms (Phase 2)

Triple Negative Breast Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 4
  • # of Trial APIs: 9